ReviewDefinitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
Section snippets
Purpose
The purpose of this statement is to provide appropriate definitions for the various stages of disease activity, define therapeutic end points in BP, and to propose an objective disease extent measure that can be used in clinical trials. The use of the same definitions and outcome measures makes the results of trials more comparable. Since definitions and outcome measures for pemphigus2, 3, 4 have been published, most trials in pemphigus and reports have begun adopting these systems or referring
Methods
An international BP definitions committee was organized in 2008, at the point when the international pemphigus definitions committee completed its similar work on pemphigus.2 The committee was an expansion of the first committee and convened 7 times over 2 years to discuss the appropriate definitions. These meetings were held at the American Academy of Dermatology (AAD) annual meeting in San Antonio, TX, in 2009 (D. F. M. and V. P. W.); European Society for Dermatologic Research in Budapest,
Observation points
The end points are illustrated and summarized (Fig 1 and Table I).
Early end points
“Baseline” is the point at which a physician starts treatment for BP.
“Control of disease activity” (disease control; beginning of consolidation phase) is defined as the point at which new lesions or pruritic symptoms cease to form and established lesions begin to heal. The time to disease control is the time between baseline and this control point.
“End of the consolidation phase” is defined as the time at which no new lesions or
Discussion and conclusion
Despite many trials evaluating therapeutic options for BP, it has been difficult to compare the results from these trials because of the large number of end points and definitions of disease. The formation of an international committee of bullous disease experts able to meet face to face on a regular basis has provided a mechanism for developing agreement on these issues for BP. This statement with agreed-upon common definitions, and the ongoing discussion and refinement of proposed common
References (10)
- et al.
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
J Am Acad Dermatol
(2008) - et al.
Reliability and convergent validity of two outcome instruments for pemphigus
J Invest Dermatol
(2009) - et al.
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study
J Invest Dermatol
(2009) - et al.
Interventions for bullous pemphigoid
Cochrane Database Syst Rev
(2010) - et al.
Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus
Eur J Dermatol
(2007)
Cited by (283)
Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity
2024, Journal of Dermatological ScienceLong-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study
2023, International ImmunopharmacologyRisk factors predisposing relapse of bullous pemphigoid at initial diagnosis: A retrospective cohort study of 205 patients
2023, International ImmunopharmacologyAssociation of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
2023, Journal of Investigative DermatologyDipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation
2023, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyThe Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid
2023, Journal of Investigative Dermatology
The International Pemphigus and Pemphigoid Foundation generously supported renting rooms at the American Academy of Dermatology and audiovisual equipment; the European Society for Dermatological Research and European Academy of Dermatology provided meeting rooms. This report was supported in part by a grant from the National Institutes of Health (K24-AR 02207) to Dr Werth.
Conflicts of interest: None declared.